Your session is about to expire
← Back to Search
Other
SY-201 Ophthalmic Solution 2.0% for Dry Eye Syndrome
Phase 1 & 2
Waitlist Available
Research Sponsored by Seinda Pharmaceutical Guangzhou Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 days
Summary
This trial is testing an eye drop treatment called SY-201 Ophthalmic Solution. It aims to see if the eye drops are safe and effective for people who have dry eye disease. The study will compare the eye drops to another group over a few months.
Eligible Conditions
- Dry Eye Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 60 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Eye dryness score
Total corneal fluorescein staining
Secondary study objectives
Adverse event
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: SY-201 Ophthalmic Solution 2.0%Experimental Treatment1 Intervention
SY-201 Ophthalmic Solution 2.0%
Group II: SY-201 Ophthalmic Solution 1.0%Experimental Treatment1 Intervention
SY-201 Ophthalmic Solution 1.0%
Group III: SY-201 Ophthalmic Solution 0.5%Experimental Treatment1 Intervention
SY-201 Ophthalmic Solution 0.5%
Group IV: SY-201 Ophthalmic Solution VehiclePlacebo Group1 Intervention
SY-201 Ophthalmic Solution Vehicle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SY-201 Ophthalmic Solution 2.0%
2022
Completed Phase 2
~210
SY-201 Ophthalmic Solution 0.5%
2022
Completed Phase 2
~210
SY-201 Ophthalmic Solution 1.0%
2022
Completed Phase 2
~210
Find a Location
Who is running the clinical trial?
Seinda Pharmaceutical Guangzhou CorporationLead Sponsor
Share this study with friends
Copy Link
Messenger